Status of chloroquine and hydroxychloroquine in COVID-19 infection


  • Savita Ramesh Shahani Department of Pharmacology, MGM Medical College, Navi Mumbai, Maharashtra, India
  • Lokesh R. Shahani Department of Psychiatry and Behavioural Science, McGovern Medical School, Houston, Texas, USA



Chloroquine hydroxychloroquine, COVID-19, SARS-CoV-2


COVID-19 causing virus is a single stranded RNA virus which has spread across the globe causing human respiratory tract infection. The novel virus which started from Wuhan was named as Wuhan coronavirus or 2019 novel corona virus (2019-nCov) by the Chinese researchers. The international committee on taxonomy of viruses named the virus as SARS-CoV-2 and the disease as COVID-19. There is preliminary in vitro evidence of the ability of CQ and HCQ to inhibit SARS-CoV-2 activity. Various small group clinical studies conducted in china indicated efficacy of chloroquine and hydroxychloroquine in Covid-19 cases but results were inconclusive. Based on these studies national agencies in various countries issued guidelines mentioning that chloroquine and Hydroxychloroquine are only to be used in clinical trials or emergency use programs. However, USFDA does not recommend use of both these drugs for treatment of COVID-19 cases. Chloroquine and hydroxychloroquine are known to produce dose dependent toxicity including fatal arrhythmias therefore its possible benefit has to be assessed against its risk. Large number of international and national studies are ongoing to assess exact status of chloroquine and hydroxychloroquine for treatment and prophylaxis of COVID-19 infection. Based on these results ICMR recommend to use hydroxychloroquine for prophylaxis of COVID-19 in India and hydroxychloroquine has been is included  in schedule H1 hence they can be sold by pharmaceutical chemists only strictly with a valid prescription and require record to be maintained but chloroquine is still under schedule H which require to be sold with prescription. 

Author Biographies

Savita Ramesh Shahani, Department of Pharmacology, MGM Medical College, Navi Mumbai, Maharashtra, India

Professor in Department of Pharmacology

Lokesh R. Shahani, Department of Psychiatry and Behavioural Science, McGovern Medical School, Houston, Texas, USA

Department of Psychiatry and Behavioral Science

Assistant Professor


Lai C, Shih T, Ko W, Tang H, Hsueh P. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-71.

Krafts K, Hempelmann E, Stania SA. From methylene blue to chloroquine: a brief review of the development of an antimalarial therapy. Parasitology Res. 2012;111(1):1-6.

Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodioquine clinical applications. Clin Pharmacokinet. 1996;30:263-99.

Central Drugs Standard Control Organization. Directorate General of Health Services. Ministry of Health and Family Welfare. Government of India. Adverse drug reaction related notifications. Available at: Notifications/Adverse Drug Reaction Related Notifications. Accessed on 3 March 2020.

Finbloom DS, Silver K, Newsome DA, Gunkel R. Comparison of Hydroxychloroquine and Chloroquine Use and the Development of Retinal Toxicity. J Rheumatol. 1985;12(4):692-4.

Bhagwan NV, Chung EH. Water, Acids, Bases, and Buffers. In Essentials of Medical Biochemistry with Clinical cases by (Second Edition). 2015, Pages11-20. Elsevier Acedemic Press.

Hempelmann E. Hemozoin biocrystallization in Plasmodium falciparum and the antimalarial activity of crystallization inhibitors. Parasitology Res. 2007;100(4):671-6.

Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases. Lancet Infectious Diseases. 2003;3(11):722-7.

Keyaerts E, Vijgen L, Maes P, Neyts J, Ranst VM. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004;323(1):264-8.

Liu J, Cao R, Xu M, Wan X, Zhang H. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6(1):1-4.

Yao X, Ye F, Zhang M, Cui C, Huang B. Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;9:237.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-71.

Bari AMA. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacol Res Perspect. 2017;5(1):e00293.

Xue J, Moyer A, Peng B, Wu J, Hannafon BN. Chloroquine is a zinc ionophore. PloS One. 2014;9(10):e109180.

Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72-3.

Huang M, Tang T, Pang P. Treating COVID-19 with Chloroquine. J Mol Cell Biol. 2020;12(4):322-5.

National Health Commission. Interpretation of the Sixth Edition of the Guidance for COVID-19: Prevention, Control, Diagnosis, and Management. Available at: http://www.nhc. 002/54e1ad5c2aac45c19eb541799bf6 37e9.shtml. (in Chinese).

Physicians work out treatment guidelines for coronavirus. (in Korean). 13 February 2020. Accessed on 17 March 2020.

Azioni intraprese per favorire la ricerca e l'accesso ai nuovi farmaci per il trattamento del COVID-19. (in Italian). Retrieved 18 March 2020.

RADM Denise M. Hinto. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine. Available at: Hydroxychloroquine. Accessed on 15 June 2020.

COVID-19: chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes. European Medicines Agency. Available at: https://www.ema.europa. eu/en/documents/press-release/covid-19-chloroquinehydroxychloroquine-only-be-used-clinical-trialsemergency-use-programmes_en.pdf. Accessed on 15 June 2020.

National Taskforce for COVID-19. Advisory on the use of hydroxy-chloroquine as prophylaxis for SARS-CoV-2 infection; 2020. Available at: ychloroquinasprophylaxisforSARSCoV2infecti on.pdf. Accessed on 15 June 2020.

Borba M, Val F, Sampaio V, Alexandre M, Melo G. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection A Randomized Clinical Trial. JAMA Netw Open. 2020;3(4):208857.

Research, Center for Drug Evaluation and (24 April 2020). FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems FDA. Available at: Accessed on 15 June 2020.

Gautret P, Lagier J, Parola P, Hoang V, Meddeb L. Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Open-Label Non-Randomized Clinical Trial. Int J Anti-microb Agents. 2020:105949.

Chen J, Liu D, Liu L. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID19). Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020;49(2):215-9.

Boulware R, Pullen F, Bangdiwala S, Pastick A, Lofgren M. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for COVID-19. 3 June 2020, at

Murphy M, Carmichael AJ. Fatal toxic epidermal necrolysis associated with hydroxychloroquine. Clin Exp Dermatol. 2001;26:457-8.

Makin A, Wendon J, Fitt S, Portmann B, Williams R. Fulminant hepatic failure secondary to hydroxychloroquine. Gut. 1994;35:569-70.

Malviya A. Ventricular arrhythmia risk due to chloroquine/hydroxychloroquine treatment for COVID-19: Should it be given. Indian Heart J. 2020;72(2):131-2.

Trial of Treatments for COVID-19 in Hospitalized Adults (discovery). Clinical identifier: NCT04315948. Available at

The Vietnam Chloroquine Treatment on COVID-19 (VICO). Clinical identifier: NCT04328493. Available at

Multi-site Adaptive Trials Using Hydroxy-chloroquine for COVID-19 (match). Clinical identifier: NCT04370262. Available at

Freedberg D, Joseph C, Wang T, Tracey K, Callahan M. Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study. Gastroenterology. Article in press.

Chloroquine for Mild Symptomatic and Asymptomatic COVID-19. Clinical identifier: NCT04333628. Available at

Chloroquine/Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting (COPCOV). Clinical identifier: NCT04303507. Available at Accessed on 15 June 2020.

A randomized controlled trial of hydroxychloroquine prophylaxis for Healthcare Workers exposed to COVID-19. CTRI/2020/05/025067 (Registered on: 06/05/2020). Available at CTRI/2020/03/024402. Accessed on 31 March 2020.

Randomized Controlled Trial to compare efficacy of hydroxychloroquine alone and in combination with azithromycin in treatment of COVID-19. CTRI/2020/04/024904 (Registered on 28 April 2020). Available at,%2743130det%27. Accessed on 15 June 2020.

Open labelled Randomized controlled trial to study the effect of Chloroquine in addition to standard therapy in COVID-19 patients. CTRI/2020/04/024479 (Registered on 7 April 2020). Available at,%2742713det%27. Accessed on 15 June 2020.

Hydroxy Chloroquine, in open labelled, Randomized intervention for prevention of new infection and adverse outcomes following COVID-19 infection- A Tertiary Hospital based study. CTRI/2020/03/024402 (Registered on 31 March 2020. Available at:,%2742638det%27. Accessed on 15 June 2020.

‘Solidarity’ clinical trial for COVID-19 treatments. Available at: diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments. Accessed on 15 June 2020.

Wong 2020 Wong YK, Yang J, He K. Caution and clarity required in the use of chloroquine for COVID-19. Lancet Rheumatology. 2020 April 2 (Epub ahead of print).

CDC 2020 Centers for Disease Control and Prevention. Interim guidelines for collecting, handling, and testing clinical specimens from persons for Coronavirus Disease 2019 (COVID-19). Available at: Accessed on 14 April 2020.

General Office of the National Health Commission of the People’s Republic of China. Diagnosis and treatment protocol for COVID-19 (trial version 7). Available at: s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml (Chinese). Accessed on 23 March 2020.

Mehra M, Desai S, Ruschitzka F, Patel A. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Available at: Accessed on 22 May 2020.

WHO Halts Hydroxychloroquine Trial Over Safety Concerns? Available at coronavirus-live-updates/2020/05/25/861913688/ who-halts-hydroxychloroquine-trial-over-safety-concerns. Accessed on 15 June 2020.

WHO resumes hydroxychloroquine study for COVID-19, after reviewing safety concerns? Available at: who-resuming-hydroxychloroquine-study-for-covid-19. Accessed on 3 June 2020.

49-ICMR Issues Revised Advisory on Use of Hydroxychloroquine. Available at: https://www. Accessed on 15 June 2020.

The gazette of India: extraordinary part II Sec. 3(i). G.S.R. 219(E). Notification New Delhi. Available at: Accessed on 26 March 2020.




How to Cite

Shahani, S. R., & Shahani, L. R. (2020). Status of chloroquine and hydroxychloroquine in COVID-19 infection. International Journal of Basic & Clinical Pharmacology, 9(8), 1301–1309.



Review Articles